메뉴 건너뛰기




Volumn 92, Issue 1, 2011, Pages 48-53

Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy

Author keywords

High dose IVIG; HLA specific antibodies; Positive crossmatch; Pronase treatment; Rituximab

Indexed keywords

HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; PANEL REACTIVE ANTIBODY; RITUXIMAB;

EID: 79959674425     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821eab8a     Document Type: Article
Times cited : (30)

References (26)
  • 2
    • 38449089313 scopus 로고    scopus 로고
    • The problem of transplanting the sensitized patient: Whose problem is it?
    • Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? Front Biosci 2008; 13: 1396.
    • (2008) Front Biosci , vol.13 , pp. 1396
    • Jackson, A.M.1    Zachary, A.A.2
  • 3
    • 0037184308 scopus 로고    scopus 로고
    • All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies
    • Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
    • (2002) Transplantation , vol.74 , pp. 1192
    • Lee, P.C.1    Terasaki, P.I.2    Takemoto, S.K.3
  • 5
    • 3042743987 scopus 로고    scopus 로고
    • National conference to assess antibody-mediated rejection in solid organ transplantation
    • Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
    • (2004) Am J Transplant , vol.4 , pp. 1033
    • Takemoto, S.K.1    Zeevi, A.2    Feng, S.3
  • 6
    • 47549105407 scopus 로고    scopus 로고
    • Rituximab and intravenous immune globulin for desensitization during renal transplantation
    • Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
    • (2008) N Engl J Med , vol.359 , pp. 242
    • Vo, A.1    Lukovsky, M.2    Toyoda, M.3
  • 7
    • 77951823581 scopus 로고    scopus 로고
    • Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation
    • Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
    • (2010) Transplantation , vol.89 , pp. 1095
    • Vo, A.1    Peng, A.2    Toyoda, M.3
  • 8
    • 33644927503 scopus 로고    scopus 로고
    • Intravenous gammablobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
    • Jordan SC, Vo AA, Peng A, et al. Intravenous gammablobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
    • (2006) Am J Transplant , vol.6 , pp. 459
    • Jordan, S.C.1    Vo, A.A.2    Peng, A.3
  • 9
    • 0042838104 scopus 로고    scopus 로고
    • Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients
    • Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
    • (2003) Transplantation , vol.76 , pp. 631
    • Jordan, S.C.1    Vo, A.2    Bunnapradist, S.3
  • 10
    • 9644262465 scopus 로고    scopus 로고
    • Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial
    • Jordan SC, Tyan DB, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial. J AmSoc Nephrol 2004; 15: 3256.
    • (2004) J AmSoc Nephrol , vol.15 , pp. 3256
    • Jordan, S.C.1    Tyan, D.B.2    Stablein, D.3
  • 11
    • 33644927503 scopus 로고    scopus 로고
    • Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
    • Jordan SC, Vo A, Peng A, et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
    • (2006) Am J Transplant , vol.6 , pp. 459
    • Jordan, S.C.1    Vo, A.2    Peng, A.3
  • 12
    • 11144232667 scopus 로고    scopus 로고
    • Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective
    • Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant 2004; 8: 535.
    • (2004) Pediatr Transplant , vol.8 , pp. 535
    • Montgomery, R.A.1    Zachary, A.A.2
  • 13
    • 32544450007 scopus 로고    scopus 로고
    • Desensitization protocols improving access and outcome in transplantation
    • Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol 2005; 5: 373.
    • (2005) Clin Appl Immunol , vol.5 , pp. 373
    • Zachary, A.A.1    Montgomery, R.A.2    Leffell, M.S.3
  • 14
    • 30744475438 scopus 로고    scopus 로고
    • Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient
    • Crew RJ, Ratner LE. Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient. Semin Dial 2005; 18: 474.
    • (2005) Semin Dial , vol.18 , pp. 474
    • Crew, R.J.1    Ratner, L.E.2
  • 15
    • 18144419717 scopus 로고    scopus 로고
    • Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin
    • Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.HumImmunol 2005; 66: 364.
    • (2005) HumImmunol , vol.66 , pp. 364
    • Zachary, A.A.1    Montgomery, R.A.2    Leffell, M.S.3
  • 16
    • 34247241237 scopus 로고    scopus 로고
    • 14th internationalHLA and immunogenetics workshop: Report on understanding antibodies in transplantation
    • Zachary AA, Montgomery RA, Jordan SC, et al. 14th internationalHLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007; 69: 160.
    • (2007) Tissue Antigens , vol.69 , pp. 160
    • Zachary, A.A.1    Montgomery, R.A.2    Jordan, S.C.3
  • 17
    • 56049093677 scopus 로고    scopus 로고
    • Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy
    • Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
    • (2008) Transplantation , vol.86 , pp. 820
    • Reinsmoen, N.L.1    Lai, C.H.2    Vo, A.3
  • 18
    • 3042651580 scopus 로고    scopus 로고
    • Evolution of HLA antibody detection: Technology emulating biology
    • Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
    • (2004) Immunol Res , vol.29 , pp. 41
    • Bray, R.A.1    Nickerson, P.W.2    Kerman, R.H.3
  • 19
    • 4444241202 scopus 로고    scopus 로고
    • Pronase treatment facilitates alloantibody flow cymetric and cytotoxic crossmatching in the presence of rituximab
    • Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cymetric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65: 803.
    • (2004) Hum Immunol , vol.65 , pp. 803
    • Bearden, C.M.1    Agarwal, A.2    Book, B.K.3
  • 20
    • 0028127304 scopus 로고
    • Phase i clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
    • Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457.
    • (1994) Blood , vol.84 , pp. 2457
    • Maloney, D.G.1    Liles, T.M.2    Czerwinski, D.K.3
  • 21
    • 12844251978 scopus 로고    scopus 로고
    • In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
    • Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55.
    • (2004) Hum Antibodies , vol.13 , pp. 55
    • Sidner, R.A.1    Book, B.K.2    Agarwal, A.3
  • 22
    • 0000524707 scopus 로고    scopus 로고
    • The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin's lymphoma (NHL) cell lines
    • Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88(suppl 1): 637.
    • (1996) Blood , vol.88 , Issue.SUPPL. 1 , pp. 637
    • Maloney, D.G.1    Smith, B.2    Appelbaum, F.R.3
  • 23
    • 0037306893 scopus 로고    scopus 로고
    • In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    • Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949.
    • (2003) Blood , vol.101 , pp. 949
    • Manches, O.1    Lui, G.2    Chaperot, L.3
  • 24
    • 33846185024 scopus 로고    scopus 로고
    • The effect of desensitization protocols on human splenic B-cell population in vivo
    • Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell population in vivo. Am J Transplant 2007; 7: 402.
    • (2007) Am J Transplant , vol.7 , pp. 402
    • Ramos, E.J.1    Pollinger, H.S.2    Stegall, M.D.3
  • 25
    • 20344398005 scopus 로고    scopus 로고
    • B-cell development: The hematopoietic hierarchy and B-lineage commitment
    • Hoffman, ed., Churchill Livingstone Elsevier, Philadelphia
    • Dorshkind K, Rawlings DJ. B-cell development: The hematopoietic hierarchy and B-lineage commitment. In: Hoffman, ed. Hematology: Basic principles and practice, [ed. 4]. Churchill Livingstone Elsevier, Philadelphia 2005.
    • (2005) Hematology: Basic Principles and Practice, [Ed. 4]
    • Dorshkind, K.1    Rawlings, D.J.2
  • 26
    • 79959664245 scopus 로고    scopus 로고
    • Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay
    • Lai CH, Okhovat J, Ong G, et al. Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay. Hum Immunol 2010; 71: S62.
    • (2010) Hum Immunol , vol.71
    • Lai, C.H.1    Okhovat, J.2    Ong, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.